Journal profile · Pharmacology & Pharmacy
Expert Opinion on Emerging Drugs
ISSN 1472-8214 · eISSN 1744-7623 · Taylor and Francis Ltd. · ENGLAND · Quarterly · Founded 2001
Expert Opinion on Emerging Drugs: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 4.39; subscription journal; median 115 days to acceptance (52 articles, last 24 months); community-reported acceptance: fairly easy; 25 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Expert Opinion on Emerging Drugs is published by Taylor and Francis Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Asthma and respiratory diseases, Retinal Diseases and Treatments and Cancer Immunotherapy and Biomarkers, together about 15.9% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.
Source: LetPub
Research area (LetPub): Pharmacology & Pharmacy
Main research topics OpenAlex counts of recent articles; shares are approximate
- Asthma and respiratory diseasesMedicine5.6%
- Retinal Diseases and TreatmentsMedicine5.2%
- Cancer Immunotherapy and BiomarkersMedicine5%
- Lung Cancer Treatments and MutationsMedicine5%
- CAR-T cell therapy researchMedicine4.9%
- Psoriasis: Treatment and PathogenesisImmunology and Microbiology4.5%
- HER2/EGFR in Cancer ResearchMedicine4.5%
- Rheumatoid Arthritis Research and TherapiesMedicine4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.39LetPub ·
- CiteScore 2026-06
- 5.9LetPub ·
- SJR 2026-06
- 0.91LetPub ·
- SNIP 2026-06
- 0.92LetPub ·
- h-index
- 43LetPub ·
- h-index
- 64OpenAlex ·
- i10-index
- 593OpenAlex ·
- 2-year mean citedness
- 4.97OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 4.69%LetPub ·
Volume
- Articles per year
- 12LetPub ·
Articles by year OpenAlex count · 1,033 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 21 | 9 | 5 |
| 2025 | 25 | 11 | 84 |
| 2024 | 33 | 12 | 304 |
| 2023 | 29 | 11 | 207 |
| 2022 | 35 | 11 | 364 |
| 2021 | 34 | 2 | 469 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
115 daysMedian, submission to acceptance · P25–P75 72 days – 162 days
- Acceptance to online
- median 9 days (52 articles)
- Submission to online
- median 123 days
- Sample
- 52 articles with submission and acceptance dates (48 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Taylor and Francis Ltd.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Quarterly
- Founded
- 2001
- ISSN
- 1472-8214
- Electronic ISSN
- 1744-7623
- Official links
- Journal homepage ↗OpenAlex
FAQ
Frequently asked questions about Expert Opinion on Emerging Drugs
What CAS zone is Expert Opinion on Emerging Drugs in?
In the 2025 upgraded edition of the CAS Journal Ranking, Expert Opinion on Emerging Drugs is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Expert Opinion on Emerging Drugs?
The latest impact factor listed by LetPub is 4.39; CiteScore 5.9, h-index 64.
How long does peer review take at Expert Opinion on Emerging Drugs?
Based on the dates recorded on 52 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 115 days (interquartile range 72–162 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Expert Opinion on Emerging Drugs?
According to LetPub and DOAJ records, Expert Opinion on Emerging Drugs is indexed in SCIE and Scopus.
Is Expert Opinion on Emerging Drugs open access, and what is the APC?
Expert Opinion on Emerging Drugs is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .